Alopecia Areata study: Ritlecitinib
Official title A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
ClinicalTrials.gov ID: NCT07733765
What this study is testing
What is Ritlecitinib 100 mg?
Ritlecitinib 100 mg is an investigational medicine, taken by mouth once daily, being studied as a potential treatment for alopecia areata.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to learn if ritlecitinib is safe and works for moderate alopecia areata.
- Who it's for
- People age 12 or older who have had patchy hair loss for at least 6 months but no more than 10 years and no other hair‑loss conditions.
- What's involved
- You will take a daily pill (ritlecitinib or a placebo) for 24 weeks, then possibly switch to a different dose for another 23 weeks, with clinic visits and some phone check‑ins.
- Time commitment
- The trial lasts about 57 weeks, including regular clinic visits and a follow‑up visit about 4 weeks after the last dose.
- Phase 3: a large, late-stage study
- Time commitment: about 57 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- Key 18 years or older (or the minimum age of consent in accordance with local regulations) at screening.
- Have a clinical diagnosis of AA with no other etiology of hair loss.
- Have \>20% to \<50% hair loss of the scalp, as measured by SALT.
- Current AA episode of hair loss ≥6 months and ≤10 years (Current episode is defined as the continuous period of AA-related scalp hair loss since the...
You likely can't join if
- Other types of alopecia (including, but not limited to, traction and scarring alopecia, telogen effluvium).
- Other scalp disease that may impact AA assessment (eg, scalp psoriasis, dermatitis, etc.).
- Active systemic diseases that may cause hair loss (eg, lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc).
The study team makes the final eligibility decision.
Where it is enrolling
- Encinitas, California, United States
- Miami, Florida, United States
- Indianapolis, Indiana, United States
- Boston, Massachusetts, United States
- Troy, Michigan, United States
- Chapel Hill, North Carolina, United States
- Charlotte, North Carolina, United States
- Bexley, Ohio, United States
- Portland, Oregon, United States
- Plymouth Meeting, Pennsylvania, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Winnipeg, Manitoba, Canada
- Oakville, Ontario, Canada
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- Québec, Quebec, Canada
- Shanghai, Shanghai Municipality, China
- Kitakyushu-shi, Fukuoka, Japan
- Hamamatsu, Shizuoka, Japan
+ 7 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 57 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Encinitas, California, United States; Miami, Florida, United States; Indianapolis, Indiana, United States; Boston, Massachusetts, United States; Troy, Michigan, United States; Chapel Hill, North Carolina, United States and 21 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.